Since NASH-HCC is a condition with limited therapeutic options and taking into account the involvement of cathepsins in both processes, targeting specific cathepsins might be a viable therapeutic option. The gene discussed is CTSS; the disease is metabolic dysfunction-associated steatohepatitis.